MDxHealth SA
MDXH3.530USD
+0.130+3.82%
Handelsschluss 02/06, 16:00（ET）Kurse um 15 Minuten verzögert
174.73MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über MDxHealth SA Unternehmen
MDxHealth SA is a Belgium-based healthcare company which provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The Company’s tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, as well as prediction of response to a specific therapy. Its tests include ConfirmMDx for Prostate Cancer, SelectMDx for Prostate Cancer, PredictMDx for Glioblastoma and AssureMDx for Bladder Cancer. The Company's corporate operations are based in Herstal, Belgium, as well as Irvine, the United States, and its laboratory operations are based in Nijmegen, the Netherlands, as well as Irvine, the United States.
MDxHealth SA Informationen
BörsenkürzelMDXH
Name des UnternehmensMDxHealth SA
IPO-datumJun 26, 2006
CEOMr. Michael K. McGarrity
Anzahl der mitarbeiter312
WertpapierartOrdinary Share
GeschäftsjahresendeJun 26
AddresseCAP Business Center
StadtHERSTAL
BörseNASDAQ Capital Market Consolidated
LandBelgium
Postleitzahl4040
Telefon3243642070
Websitehttps://mdxhealth.com/
BörsenkürzelMDXH
IPO-datumJun 26, 2006
CEOMr. Michael K. McGarrity
Führungskräfte von MDxHealth SA
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Michael K. McGarrity
Mr. Michael K. McGarrity
Chief Executive Officer, Director
Chief Executive Officer, Director
95.00K
--
Mr. Michael Holder
Mr. Michael Holder
Director
Director
--
--
Mr. Mark Shaffar
Mr. Mark Shaffar
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. Christopher (Chris) Thibodeau
Mr. Christopher (Chris) Thibodeau
Executive Vice President & U.S. Chief Operations Officer
Executive Vice President & U.S. Chief Operations Officer
--
--
Dr. Sanford S Siegel, M.D.
Dr. Sanford S Siegel, M.D.
Director
Director
--
--
Mr. Joseph (Joe) Sollee
Mr. Joseph (Joe) Sollee
Executive Vice President, Chief Compliance Officer, General Counsel
Executive Vice President, Chief Compliance Officer, General Counsel
--
--
Mr. John Bellano
Mr. John Bellano
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. Rudi Marien
Mr. Rudi Marien
Non-Executive Director
Non-Executive Director
--
--
Mme. Ruth Devenyns
Mme. Ruth Devenyns
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Walter M. (Wally) Narajowski
Mr. Walter M. (Wally) Narajowski
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Michael K. McGarrity
Mr. Michael K. McGarrity
Chief Executive Officer, Director
Chief Executive Officer, Director
95.00K
--
Mr. Michael Holder
Mr. Michael Holder
Director
Director
--
--
Mr. Mark Shaffar
Mr. Mark Shaffar
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. Christopher (Chris) Thibodeau
Mr. Christopher (Chris) Thibodeau
Executive Vice President & U.S. Chief Operations Officer
Executive Vice President & U.S. Chief Operations Officer
--
--
Dr. Sanford S Siegel, M.D.
Dr. Sanford S Siegel, M.D.
Director
Director
--
--
Mr. Joseph (Joe) Sollee
Mr. Joseph (Joe) Sollee
Executive Vice President, Chief Compliance Officer, General Counsel
Executive Vice President, Chief Compliance Officer, General Counsel
--
--
Umsatzaufteilung
Währung: USDAktualisiert: Tue, Jan 6
Währung: USDAktualisiert: Tue, Jan 6
FY2023
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Nach RegionUSD
Name
Umsatz
Anteil
United States of America
69.71M
99.31%
Europe
476.00K
0.68%
Rest of the world
9.00K
0.01%
Nach Geschäftsbereich
Nach Region
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Aktionärsstatistik
Aktualisiert: Sat, Feb 7
Aktualisiert: Sat, Feb 7
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Bleichroeder LP
14.91%
AWM Investment Company, Inc.
10.55%
MVM Partners LLP
9.50%
Lytton (Laurence W)
6.36%
Genomic Health, Inc.
4.93%
Andere
53.75%
Aktionäre
Aktionäre
Anteil
Bleichroeder LP
14.91%
AWM Investment Company, Inc.
10.55%
MVM Partners LLP
9.50%
Lytton (Laurence W)
6.36%
Genomic Health, Inc.
4.93%
Andere
53.75%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
20.60%
Investment Advisor/Hedge Fund
14.94%
Venture Capital
9.52%
Individual Investor
6.67%
Corporation
4.93%
Hedge Fund
1.21%
Research Firm
0.12%
Andere
42.00%
Institutionelle Beteiligung
Aktualisiert: Thu, Jan 1
Aktualisiert: Thu, Jan 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q4
71
22.89M
46.25%
-1.34M
2025Q3
49
21.80M
44.04%
-2.18M
2025Q2
45
28.07M
56.71%
+2.44K
2025Q1
47
29.82M
60.25%
-710.83K
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Bleichroeder LP
7.38M
14.91%
--
--
Sep 30, 2025
AWM Investment Company, Inc.
5.22M
10.55%
--
--
Sep 30, 2025
MVM Partners LLP
4.70M
9.5%
--
--
Sep 30, 2025
Lytton (Laurence W)
3.15M
6.36%
-799.84K
-20.25%
Sep 30, 2025
Genomic Health, Inc.
2.44M
4.93%
+1.50M
+159.38%
Sep 27, 2024
Samjo Capital, LLC
1.45M
2.92%
-89.90K
-5.86%
Sep 30, 2025
Perkins Capital Management, Inc.
1.40M
2.83%
-17.42K
-1.23%
Sep 30, 2025
Kennedy Capital Management LLC
392.65K
0.79%
+344.85K
+721.41%
Sep 30, 2025
Northern Trust Global Investments Limited
305.07K
0.62%
-106.86K
-25.94%
Sep 30, 2025
FreeGulliver LLC
252.89K
0.51%
+129.35K
+104.70%
Sep 30, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Dec 6
Aktualisiert: Sat, Dec 6
Name
Anteil
iShares Micro-Cap ETF
0.04%
iShares Micro-Cap ETF
Anteil0.04%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
